文献速递类风湿关节炎

达标治疗策略对类风湿关节炎母婴结局的影响:多中心真实世界ANSWER队列研究

Effect of treat-to-target strategies on maternal and neonatal outcomes of rheumatoid arthritis: a multicentre real-world ANSWER cohort study.
PubMed 文献 · Rheumatology (Oxford) · 2026-01-01

该回顾性观察研究分析日本ANSWER多中心队列2013至2023年118例类风湿关节炎妊娠,评估达标治疗(T2T)的可行性与影响。约85%患者孕期维持缓解或低疾病活动度,产后疾病活动度升高。孕期继续使用生物制剂改善病情抗风湿药(bDMARDs)者第二、三孕期DAS28-CRP显著低于停药者。

要点

  • 118例妊娠中92.8%实现足月分娩,中位出生体重2949 g,约85%孕期维持缓解或低疾病活动度。
  • 孕期继续bDMARDs者(n=35)第二、三孕期DAS28-CRP显著低于停药者(n=24)(P=0.007和P=0.0002)。
  • 依那西普或培塞利珠单抗与良好疾病控制相关;糖皮质激素使用与疾病活动度升高相关。

核心结论

  • T2T管理包括选择性继续使用bDMARDs,与良好的母体疾病控制和令人安心的妊娠结局相关。
  • 原文指出缺乏长期随访是局限性,这些发现提供支持该方法的真实世界证据。
  • 原文结论要求更大规模的前瞻性研究来确认早期产后之后的母婴安全性。

研究设计与样本

  • 回顾性观察研究,分析日本ANSWER多中心队列2013至2023年8家日本学术机构的118例类风湿关节炎妊娠。
  • 在孕前、每个孕期和产后评估临床特征、治疗方案和基于C反应蛋白的28关节疾病活动度评分(DAS28-CRP),并分析妊娠和新生儿结局。

主要发现

  • 118例妊娠中92.8%实现足月分娩,中位出生体重2949 g。
  • 约85%患者整个孕期维持缓解或低疾病活动度,产后疾病活动度升高。
  • 孕期继续bDMARDs者(n=35)第二孕期DAS28-CRP显著低于停药者(n=24)(P=0.007),第三孕期亦显著低于停药者(P=0.0002)。
  • 依那西普或培塞利珠单抗使用与良好疾病控制相关;托珠单抗(n=6)或阿巴西普(n=2)与不良母婴结局无关;糖皮质激素使用与疾病活动度升高相关。
  • 柳氮磺吡啶使用与出生体重增加相关(P=0.003),与胎龄相关(P=0.051)。

临床怎么用

  • 原文结论认为T2T管理包括选择性继续使用bDMARDs与良好母体疾病控制和令人安心的妊娠结局相关,并提供真实世界证据支持该方法。
  • 原文建议需要更大规模的前瞻性研究来确认早期产后之后的母婴安全性。

局限性

  • 原文指出缺乏长期随访是局限性。
  • 原文结论要求更大规模的前瞻性研究来确认早期产后之后的母婴安全性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: We evaluated real-world disease activity, treatment patterns and pregnancy outcomes in women with rheumatoid arthritis (RA) utilizing a multicentre Japanese cohort. Feasibility and impact of a treat-to-target (T2T) approach during pregnancy were also examined. METHODS: A retrospective observational study analysed 118 pregnancies in patients with RA from the multicentre ANSWER cohort (2013-2023) across eight Japanese academic institutions. Clinical characteristics, treatment regimens and RA Disease Activity Scores of 28 joints based on C-reactive protein (DAS28-CRP) were assessed at preconception, during each trimester and postpartum. Pregnancy and neonatal outcomes were analysed. RESULTS: Of 118 pregnancies, 92.8% achieved full-term deliveries (median birthweight: 2949 g). Remission or low disease activity was maintained in ∼85% of patients throughout pregnancy, with increased postpartum disease activity. Patients who continued biologic disease-modifying antirheumatic drugs (bDMARDs) during pregnancy (n = 35) exhibited significantly lower DAS28-CRP scores during the second and third trimesters compared with those who discontinued (n = 24) (P = 0.007 and P = 0.0002, respectively). Etanercept or certolizumab pegol use was associated with favourable disease control. Tocilizumab (n = 6) or abatacept (n = 2) was not associated with adverse maternal or neonatal outcomes. Glucocorticoid use was associated with increased disease activity. Salazosulfapyridine use correlated with increased birth weight (P = 0.003) and gestational age (P = 0.051). CONCLUSION: T2T management, including selective continuation of bDMARDs, was associated with favourable maternal disease control and reassuring pregnancy outcomes. Although the absence of long-term follow-up is a limitation, these findings provide real-world evidence supporting this approach. Larger prospective studies are required to confirm maternal and neonatal safety beyond the early postpartum.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Hiramatsu Y, Kotani T, Nakamura E, et al. Effect of treat-to-target strategies on maternal and neonatal outcomes of rheumatoid arthritis: a multicentre real-world ANSWER cohort study. Rheumatology (Oxford). 2026. PMID: 41134194. doi:10.1093/rheumatology/keaf558

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。